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Abstract
Background: The immense diagnostic potential of human plasma has prompted great interest and effort
in cataloging its contents, exemplified by the Human Proteome Organization (HUPO) Plasma Proteome
Project (PPP) pilot project. Due to challenges in obtaining a reliable blood plasma protein list, HUPO later
re-analysed their own original dataset with a more stringent statistical treatment that resulted in a much
reduced list of high confidence (at least 95%) proteins compared with their original findings. In order to
facilitate the discovery of novel biomarkers in the future and to realize the full diagnostic potential of blood
plasma, we feel that there is still a need for an ultra-high confidence reference list (at least 99% confidence)
of blood plasma proteins.
Methods: To address the complexity and dynamic protein concentration range of the plasma proteome,
we employed a linear ion-trap-Fourier transform (LTQ-FT) and a linear ion trap-Orbitrap (LTQ-Orbitrap)
for mass spectrometry (MS) analysis. Both instruments allow the measurement of peptide masses in the
low ppm range. Furthermore, we employed a statistical score that allows database peptide identification
searching using the products of two consecutive stages of tandem mass spectrometry (MS3). The
combination of MS3 with very high mass accuracy in the parent peptide allows peptide identification with
orders of magnitude more confidence than that typically achieved.
Results: Herein we established a high confidence set of 697 blood plasma proteins and achieved a high
'average sequence coverage' of more than 14 peptides per protein and a median of 6 peptides per protein.
All proteins annotated as belonging to the immunoglobulin family as well as all hypothetical proteins whose
peptides completely matched immunoglobulin sequences were excluded from this protein list. We also
compared the results of using two high-end MS instruments as well as the use of various peptide and
protein separation approaches. Furthermore, we characterized the plasma proteins using cellular
localization information, as well as comparing our list of proteins to data from other sources, including the
HUPO PPP dataset.
Conclusion: Superior instrumentation combined with rigorous validation criteria gave rise to a set of 697
plasma proteins in which we have very high confidence, demonstrated by an exceptionally low false peptide
identification rate of 0.29%.
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Background
Human blood plasma contains a plethora of proteins,
encompassing not only proteins that have plasma-based
functionality, but possibly every other human protein in
minute amounts as well. Circulating through the tissues,
the plasma picks up proteins that are released from their
origin due to physiological events such as tissue remode-
ling and cell death. Specific disease processes or tumors
are often characterized by plasma "signatures", which may
become obvious via changes in the plasma proteome pro-
file, for example, through over-expression of proteins.
Thus, besides being a medically relevant diagnostic tool,
the plasma is also of exceptional nature, characterized by
its complexity and its large dynamic protein concentra-
tion range. Additionally, because of the potential for every
possible human protein to be present, there is an inherent
difficulty in distinguishing between proteins truly residing
in the plasma and proteins that are released into the
plasma due to trauma or other events. Fortunately, it is to
be expected that the latter are found inconsistently and
usually only in very low concentration, below the limits of
detection.
Thirty years ago the detection of plasma proteins became
feasible with the introduction of two-dimensional (2D)-
gel electrophoresis, but the analysis of unfractionated
plasma substantially limited the number of detectable
proteins, resulting in a total of only 60 identified plasma
proteins by 1992 [1]. The combination of 2D-gel electro-
phoresis, removal of the most abundant serum proteins
with immunoaffinity chromatography, and sequential
anion-exchange and size-exclusion chromatography, and
subsequent MALDI-TOF as well as online electrospray ion
trap mass spectrometry, increased the number of distinct
plasma proteins identified to 325 eleven years later [2].
Progressively more proteins could be identified as techno-
logical advancements were introduced and different pre-
parative techniques were combined. The pilot phase of
the PPP, launched by HUPO in 2002, attempted to
address questions regarding the best technology platform
for the characterization of proteins in human plasma or
serum. The PPP investigated factors such as the influence
of various technical aspects of specimen collection and
handling, whether the most abundant plasma proteins
should be depleted, and whether anti-protease cocktails
are desirable [3,4]. In the end, 35 proteomics laboratories
in 13 countries committed to participate in the PPP. Most
of the laboratories separated their samples at the peptide
level using liquid chromatography, followed by MALDI-
or electrospray-MS2. The software used for peptide identi-
fication included Sequest, Mascot, PepMiner, Viper, Dig-
ger, and Sonar. Several investigators applied
combinations of these technologies. The bioinformatics
group at the University of Michigan was the central hub of
the project, being responsible for validating the submitted
protein identifications [5].
To complement the efforts of the PPP, we established a
reference set of plasma proteins that we are highly confi-
dent in and against which other data sets can be com-
pared. As a single lab, we clearly could not address all of
the possible technical variables addressed by the PPP. For
example, we decided to use human plasma rather than
serum in order to avoid any in vitro proteolysis processes
which may have introduced artifacts. However, in parallel
with the PPP effort, we employed depletion and pre-frac-
tionation methods to deal with the enormous complexity
and plasma protein concentration range, and we also used
protease inhibitors. Comparison of the various tech-
niques employed revealed the usefulness of some of those
techniques. We utilized hybrid LTQ-FT and -Orbitrap
mass spectrometer systems for plasma measurements
because of their superior dynamic range and mass accu-
racy, and to further increase the reliability of our data, we
employed MS3.
Methods
Plasma sample preparation and protein depletion
Blood samples analysed by FT-ICR were drawn from two
healthy male volunteers aged 39 and 46, pooled, mixed
with EDTA to prevent blood clotting, and kept on ice until
being centrifuged at 400 × g for 20 min at 4°C. If plasma
samples were not immediately used for analysis, they
were stored at -80°C until needed. To remove albumin
from plasma, the Vivapure anti-HSA kit (VivaScience,
Hannover, Germany) was used according to the instruc-
tions of the manufacturer. Protease inhibitors were added
to selected samples before albumin depletion using Pro-
tease Inhibitor Cocktail tablets (Complete, Roche Diag-
nostics, Penzberg, Germany). Depletion of 6 of the most
abundant proteins including albumin, transferrin, hap-
toglobin, alpha-1-antitrypsin, IgA and IgG was performed
using the Agilent Multiple Affinity Removal System (Agi-
lent Technologies, Waldbronn, Germany). Blood samples
to be subjected to the Orbitrap were collected and pooled
from 9 healthy individuals, 5 males (aged 35–56 years)
and 4 females (aged 26 to 40 years) with no family history
of diabetes or blood disorders. EDTA was added at sample
collection time, protease inhibitors were later added and
high abundance proteins were removed using the Agilent
Multiple Affinity Removal System described above.
Gel electrophoresis and protein digestion
Gel electrophoresis was performed with pre-cast NuPage
Bis-Tris gels (4–12%) and MES or MOPS buffer (Invitro-
gen, Carlsbad, CA) according to the manufacturer's
instructions. Alternatively, plasma samples were run on
large 4–20% Tris-glycine gradient gels. Gels were stained
with a Colloidal Blue Staining Kit (Invitrogen). ProteinBMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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bands were excised, cut into small pieces and washed at
least twice (20 min. each) with 50:50 (v/v) 50 mM
NH4HCO3/absolute HPLC-grade ethanol. Supernatants
were discarded after each washing step. The gel pieces
were dehydrated with absolute ethanol until opaque,
white and hard. Disulfide bonds were cleaved with 10
mM DTT in 50 mM NH4HCO3 buffer (not pH adjusted)
for 60 min at 56°C. Alkylation of cysteines was performed
by the addition of 55 mM iodoacteamide in 50 mM
NH4HCO3 buffer and incubation of the samples for 45
min at room temperature in the dark. Gel pieces were
washed twice in 50 mM NH4HCO3 buffer and dehydrated
with absolute ethanol, dried (Speed-Vac) and covered
with trypsin (modified sequence grade, Promega, Madi-
son, WI, U.S.A.) solution (12.5 ng/μl trypsin in 50 mM
NH4HCO3). Protein digestion was performed at 37°C
overnight and stopped by the addition of a final concen-
tration of 3% (v/v) trifluoroacetic acid (TFA). Superna-
tants were collected and gel slices were extracted at least
twice with 100% acteonitrile. Supernatants were pooled
and the acetonitrile was removed using Speed-Vac centrif-
ugation. Samples were acidified with TFA to pH ≤ 2.5,
loaded on conditioned C-18 tips, and stored at 4°C until
used for mass spectrometry.
Plasma sample separation by off-gel electrophoresis
(OGE) with subsequent 2-D gel electrophoresis for sepa-
ration evaluation was performed at Agilent (Waldbronn,
Germany). OGE fractions were treated in solution with
iodoacetamide, subsequently quenched with DTT and
concentrated using Microsep columns (molecular weight
cut-off (MWCO) 3 kDa, PALL Life Sciences, Ann Arbor,
MI, USA). Trypsin digestion, disulfide reduction and
cysteine alkylation were performed as specified above.
Nano-HPLC and mass spectrometry
Nanoscale liquid chromatography tandem mass spec-
trometry (nano-HPLC-MS/MS) was performed using an
Agilent 1100 nanoflow LC system (Agilent Technologies),
equipped with a solvent degasser, a nanoflow pump and
a thermostatted autosampler. This system was connected
to a 7 Tesla Finnegan linear quadrupole ion trap Fourier
transform (LTQ-FT) mass spectrometer and an LTQ-Orbi-
trap (Thermo Electron, Bremen, Germany). Tryptic pep-
tides were chromatographically separated on 15 cm
columns (75 μm inner diameter) packed by hand with a
methanol-based slurry of reverse-phase ReproSil-Pur C18-
AQ 3 μm resin (Dr. Maisch HPLC GmbH; Ammerbuch,
Germany) and mounted on the nanoelectrospray ion
source. Peptides were autosampled onto the packed col-
umn at a flow rate of 500 nl/min and were separated over
20 min using a linear gradient of 13–34% (v/v) ace-
tonitrile/0.5% (v/v) acetic acid. Elution occurred at a flow
rate of 250 nl/min and ionization was performed using an
applied voltage of 2.4 kV to the emitter.
Data were acquired using Xcalibur software in data-
dependent mode to facilitate automatic switching
between MS, MS2 and MS3. In the case of LTQ-FTICR sur-
vey, full scan MS spectra (from m/z 300–1,575) were
acquired in the ICR with a resolution R = 25,000 at m/z
400 (after accumulation to a target value of 5 × 106 in the
linear ion trap). The three most intense ions were sequen-
tially isolated for accurate mass measurements by FT ICR
selected ion monitoring [5] scan with 10 Da mass range,
R = 50,000 and target accumulation value of 5 × 104 ions.
Simultaneously, these were fragmented in the linear ion
trap by collision-induced dissociation (MS2) at a target
value of 5 × 104 ions. For MS3 analysis the three most
intense ions of each MS2 spectrum with m/z > 300 were
further isolated and fragmented. Each precursor ion
selected for MS2 was dynamically excluded for 30 s for
subsequent LC-MS runs. Total cycle time was approxi-
mately 3 s. General mass spectrometric conditions were as
follows: no sheath and auxiliary gas flow, ion transfer tube
temperature 100°C, collision gas pressure 1.3 mTorr, nor-
malized collision energy using wide band activation
mode was 30% for MS2 and 35% for MS3, ion selection
thresholds were 250 counts for MS2 and 5 counts for MS3.
An activation q = 0.25 and activation time of 30 ms was
applied in both MS2 and MS3 acquisition. In the case of
the LTQ-Orbitrap, the precursor ion scan MS spectra (m/z
300–1600) were acquired in the Orbitrap with resolution
R = 60,000 at m/z 400 with the number of accumulated
ions being 1 × 106. The five most intense ions were iso-
lated and fragmented in the linear ion trap (number of
accumulated ions; 3 × 104). The resulting fragment ions
were recorded in the Orbitrap with resolution R = 15,000
at m/z 400. The lock mass option enabled accurate mass
measurements in both MS and MS/MS mode. The poly-
dimethylcyclosiloxane ions generated in the electrospray
process from ambient air (protonated (Si(CH3)2O)6, m/z
445.120025) were used for internal recalibration in real
time. In data-dependent LC-MS/MS experiments dynamic
exclusion was used with 30 s exclusion duration.
Database searches
Using software available in-house (DTA Supercharge), all
MS/MS spectrum files from each LC run were converted
into peak-lists. The charges and error masses were also
assigned, and files were centroided and merged into a sin-
gle file. These were searched against the human IPI (Inter-
national Protein Index) database (versions 2.27, 2.35,
2.37, 3.03, 3.19; all versions were later converted to ver-
sion 3.25) using the Mascot search engine (Matrix Science,
London, UK) with carbamidomethyl cysteine as a fixed
modification and variable modifications, including oxi-
dized methionine (+15.99 Da), protein N-acetylaction,
deamidation [6], and Pyro (N-term QEC). Searches were
done with tryptic specificity allowing one missed cleavage
and a tolerance on mass accuracy of 5 ppm in MS modeBMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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and 0.5 Da in MS/MS mode. MS3 spectra were automati-
cally scored using MSQuant software [7] according to an
algorithm that assigns MS3 spectra to peptide fragment
sequences [8]. MSQuant is a validation tool developed in-
house that parses Mascot identifications and allows for
MS3 scoring, quantitation, and manual spectrum verifica-
tion.
Blood plasma protein database (BPPD) construction and 
associated software
Identified proteins were exported from MSQuant along
with their appropriate sequenced peptides, all of their
assigned accession numbers, Mascot peptide scores, MS3
precursor ions and other MS and MS/MS relevant data
into Microsoft Excel before being uploaded into a blood
plasma protein database. The BPPD was built in-house
using the open source relational database MySQL [9]. The
associated web-based software tools were written in Perl
[10]. The BPPD architecture stores all of the peptides for
each protein identified, the associated protein informa-
tion (including the non-redundant protein and peptide
sequences), as well as the mass spectrometry data associ-
ated with each peptide. Experimental design data is also
included to make cross-experiment comparisons possible.
To establish a 'finalized' set of proteins, stringent criteria
were applied with regard to peptide length and peptide
Mascot and MS3 scores (see Results). Note that we have
decided to exclude proteins belonging to the immu-
noglobulin family in order to facilitate comparison with
other blood plasma studies, but we have included the data
for these proteins in a supplement available on line [see
Additional file 1]. To aid in the data validation process,
several web-based software tools were developed in-
house, such as a tool to parse and reorganize the output
from MSQuant, a tool to retrieve SwissProt and NCBI
sequences and their respective annotations based on
accession numbers, as well as a 'peptide mapper', which
allows the mapping of peptides onto sequences in plain
text, FASTA, or ClustalW sequence alignment format. We
also developed other software tools for the purpose of
identifying redundancy, automating the peptide valida-
tion process and for calculating the percent peptide cover-
age. A detailed description of the software tools and
database system used here will be published elsewhere.
Decoy database search to estimate false peptide 
identification rate
In order to estimate the rate of false peptide identification
in our result set, we constructed a decoy database consist-
ing of all of the sequences of the human IPI database (ver-
sion 3.25; 67,250 sequences) in their reverse orientation,
together with the original FASTA header information.
'Reverse orientation' simply means that each protein
sequence was read and stored sequentially, beginning at
the C-terminal end and concluding at the N-terminal end.
We then extracted all of the non-redundant peptide
sequences obtained for all of the experiments we per-
formed and searched with these against the decoy data-
base that we constructed. The false error rate was reported
as the number of peptide sequences matching the decoy
database divided by the total number of non-redundant
peptides we obtained across all experiments. This number
was then converted to a percentage [11,12].
Results
Plasma experiments performed
In order to identify a set of plasma proteins with high con-
fidence and to test the usefulness of different plasma treat-
ments and separation methods, we employed several
different techniques: depletion of highly abundant pro-
teins, addition of protease inhibitors, two different pre-
fractionation methods, as well as modified mass spec-
trometry settings. We performed a total of eight different
independent experiments (Table 1).
For experiments 01_MS2 and 04_MS2_prec, plasma was
separated on a Novex 4–12% pre-cast gradient gel (gel size
8 × 8 cm) and a larger 4–20% manually poured gradient
gel (gel size 12.5 × 14 cm), respectively. The Novex gel was
cut into 29 pieces, and about 50% of the larger gel into 21
pieces. The size of the gel slices was chosen individually
for each gel depending on the protein intensity and band
size. MS and MS2 spectra were recorded in a total LC-MS
run time of 100 min for each of the 29 and 21 samples
from 01_MS2 and 04_MS2_prec, respectively. For
01_MS2 samples, scan events were performed as
described in Methods 'HPLC and Mass Spectrometry',
except that MS3 was not recorded (MS full scan, m/z
300.0 – 1500.0). For 04_MS2_prec the acquisition soft-
ware (MS full scan, m/z 300.0–1800.0) was directed to
select only peptides in the amplified mass ranges for
sequencing (m/z 350.0–450.0, 445.0–545.0, 540.0–
640.0, 635.0–735.0, 730.0–830.0, 825.0–1800.0). The 05
experiment is similar to 04_MS2_prec with respect to the
protein amount but the gel was cut into 35 fractions. Also,
MS3 was performed in addition to MS and MS2, and MS
scan events were carried out as described in Methods
'nano-HPLC and mass spectrometry' (MS full scan, m/z
300.0–1575.0). The MS run time was 100 min per sam-
ple. Compared to 05, approximately three times more
plasma protein was employed and was albumin-depleted
before gel separation in the 06_Alb_depl experiment. The
gel was cut into 28 pieces and the MS settings were basi-
cally the same for 05 and 06_Alb_depl. The addition of
Protease Inhibitors distinguishes experiment
10_Alb_depl_NL from 06_Alb_depl. Also, in
10_Alb_depl_NL, MS3 acquisition was only done in a
neutral loss-dependent fashion, in order to detect possible
phosphopeptides. As early as in the pilot phase of theBMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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HUPO project [3-5], the possible determination of post-
translational modifications of plasma proteins such as
protein phosphorylation was mentioned as an important
issue for the comprehensive analysis of the protein con-
stituents of human plasma as well as the identification of
biomarkers. Finally, in the 08_OGE and 09_OGE_6_depl
experiments, plasma proteins were not separated by 1D-
PAGE, but by off gel electrophoresis (OGE). For experi-
ment 09_OGE_6_depl, 12 mg of plasma was applied to
the Agilent Multiple Affinity Removal System (removal of
6 high abundance proteins) and 50% of the depleted pro-
tein (650 ug) was subsequently separated by OGE. For
experiment 08_OGE, plasma was directly applied to OGE.
15 fractions from each experiment were subjected to mass
spectrometry, which was performed in essentially the
same manner as mentioned for 05 and 06_Alb_depl,
except that the total run time was increased to 140 min
per fraction sample. Plasma samples that were designated
for measurement on the Orbitrap were depleted of 6 high
abundance proteins as above and run in 3 separate lanes
on a 1D-PAGE gel. Each lane was cut into 15 slices result-
ing in a total of 45 samples. The samples were analysed
separately on the Orbitrap without MS3 analysis.
Data validation and blood plasma protein database
The mass spectrometry LTQ-FT acquisition of 7 plasma
samples was designed to exploit the sensitivity and speed
advantages of the ion trap, while taking advantage of the
ultra-high mass accuracy and dynamic range of the Fou-
rier Transform ion cyclotron resonance (FT-ICR) detector.
The Orbitrap mass analyser features very high sensitivity
in MS and MSn and rapid scan rates. Its excellent mass
accuracy capabilities and high resolution are similar to
those achievable with FT-ICR instrumentation.
In total, protein and peptide identifications from 8 inde-
pendent experiments corresponding to 216 MS runs, were
combined within our Blood Plasma Protein Database
(BPPD). In addition to the stringent Mascot search criteria
(tryptic specificity, 1 missed cleavage, MS accuracy of 5
ppm and MS2 of 0.5 Da), only peptides that were checked
(highest scoring use of spectra), red (highest scoring
match of spectra), bolded (first use of spectra in the out-
put list), and had a minimum Mascot peptide score of 16
as well as a minimum length of 7 amino acids were con-
sidered for further validation.
Further validation criteria were applied as previously
described [13,14] and as defined by Mascot peptide iden-
tification/assignment software (Matrix Science, London,
UK). Briefly, proteins identified with one single peptide
were required to have an MS3 spectrum, an MS3 score,
and a total score (also known as a 'Mascot peptide score
plus MS3 score') ≥ 42, which assured with 99.9% confi-
dence that this was a correct identification. Proteins iden-
tified with one single peptide but without an available
MS3 scan were discarded regardless of their Mascot pep-
tide score. If a protein was identified with two peptides,
one of the two peptides was required to have a Mascot
peptide score ≥ 32, ensuring a minimum confidence of
99%, and the other peptide a 95% confidence (Mascot
peptide score ≥ 25) of being a correct identification. Pro-
Table 1: Plasma experiments performed.
Experiment Designated name Plasma treatment [Protein]
(μg) applied
Plasma
separation
method
MS LC-MS run
time/sample
(minutes)
Comment
Plasma_01 01_MS2 none 450 1-D PAGE MS/MS2 100
Plasma_04 04_MS2_prec none 750 1-D PAGE MS/MS2 100 Precursor selection 
within certain mass
ranges only
Plasma_05 05 none 750 1-D PAGE MS/MS2/MS3 100
Plasma_06 06_Alb_depl Albumin-depletion 1800 1-D PAGE MS/MS2/MS3 100
Plasma_10 10_Alb_depl _NL Albumin depletion, 
Protease inhibitors
1800 1-D PAGE MS/MS2/MS3 100 Neutral loss 
dependent MS3
Plasma_08 08_OGE none 1800 OGE MS/MS2/MS3 140
Plasma_09 09_OGE_6_depl Depletion of albumin,
transferrin, haptoglobin,
alpha-1-antitrypsin,
IgA and IgG
650 OGE MS/MS2/MS3 140
Plasma_11 11_Orbitrap Depletion of albumin,
transferrin, haptoglobin,
alpha-1-antitrypsin,
IgA and IgG
300 1-D PAGE MS/MS2 140
A summary of the differences in the experimental protocols between plasma experiments is shown. Each experiment has been assigned a 
meaningful "designated name" that is used in the text and in the accompanying figures and tables. Note that all experiments include MS3 
measurements with the exception of 01_MS2, 04_MS2_prec and 11_Orbitrap. The type of treatment performed on the plasma samples, if any, is 
indicated, along with the amount of material applied to the gel, the separation method employed, and the method used for MS data collection.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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teins identified with three peptides were required to have
at least one peptide with a Mascot peptide score ≥ 32
(99% confidence). In order to automate the validation
process, a Perl script was written that applied the valida-
tion rules stated above, and which also verified that each
and every peptide sequence actually mapped correctly to
the master protein sequence.
All proteins seemingly identified as a specific isoform
were manually verified. Using ClustalW and our 'peptide
mapper' software, the peptides for a particular protein
were matched to all known isoforms for this protein, and
in the case where one or more of the peptides was specific
for one and only one single isoform, this protein was
given the specific protein isoform name. If the peptides
mapped onto more than one isoform then all possible
isoforms were added to the annotation for that protein,
but not counted as separate identified proteins.
Additionally, all proteins were assigned a primary acces-
sion number; that is, an accession number and sequence
respectively (Swiss-Prot, Tremble, RefSeq, Ensembl or H-
Inv) that matched all identified peptides for a given pro-
tein. If the peptides for a given protein matched more than
one accession number/sequence, then the Swiss-Prot/
Uni-Prot number was chosen, if available.
Several checks to eliminate redundancy from the BPPD
were performed. First, all proteins with identical MW and/
or overlapping accession numbers were manually verified
using our peptide mapping software. We encountered a
substantial number of overlapping accession numbers
since Mascot provides accession number information
from many sources. In these cases all of the peptides from
all of the proteins in question were 'mapped' to all of the
possible protein sequences. Note that to say that a peptide
'maps to a sequence', we required a 100% sequence match
between the peptide(s) and the protein sequence(s) in
question. If the peptides from all of the overlapping pro-
teins were found to completely map to one of the protein
sequences, then the data was merged into one entry and
the protein name that is given in the SwissProt/Uniprot
database was chosen as the annotation for that entry. If
even one peptide failed to map during this test then that
protein remained as a separate entry in the database.
In cases where the Mascot-assigned peptides of a protein
did not match any assigned accession number/sequence,
then the peptides were used to perform a BLAST search for
short, nearly exact matches. If there was no unambiguous
identification possible following this step then the protein
and peptides were discarded.
After removal of the first set of redundant entries, all
remaining entries in the BPPD were aligned to each other
using All vs. All BLAST [15] and all alignments with 90%
or higher identity were again manually checked for redun-
dancy using a ClustalW alignment and our peptide map-
ping software.
As a final redundancy check, we performed a database
search with the aid of a Perl script we developed which
employs a peptide mapping approach to identify redun-
dancy. We located redundancy by identifying protein
entries whose peptides also completely mapped to other
protein entries. In these cases we reassigned the peptides
belonging to the redundant protein entries to one com-
mon master protein entry. During this stage we were
somewhat surprised to discover that not all instances of
redundancy for highly homologous proteins were
detected in the all vs. all BLAST step that we carried out
previously. For example, isoforms 2 and 4 of Fibronectin
1 were not identified as redundant using the All vs. All
BLAST tool with a cutoff of 90% identity due to a poor
alignment of the sequences by the BLAST program. The
isoform 2 and 4 sequences of Fibronectin 1 share 100%
sequence identity, except for a central region within iso-
form 2 which makes this isoform 91 amino acids longer
than isoform 4. In retrospect, employment of the peptide
mapping approach as the first step rather than as the last
step in redundancy checking would probably have ren-
dered all of the other redundancy checks that we per-
formed unnecessary.
Our elaborate validation process is reflected in the results
of the decoy database analysis in which we searched all of
the human International Protein Index (IPI) sequences
(67,250) in their reversed orientation, which yielded 30
matches out of a possible 10,378. This gave a false peptide
identification rate of 0.29 percent. In this analysis, the
possible peptides (10,018) for the search were calculated
by assembling all of the peptide sequences across all
experiments and removing all of the peptides identifying
immunoglobulins. Redundancy among the peptide
sequences was then eliminated. The number of 10,018
peptides differs from those seen below in that it includes
the peptides for all proteins (excluding immunoglobu-
lins) across all experiments prior to validation.
High confidence set of plasma proteins
By combining the eight plasma experiments as listed in
Table 1 and after removal of redundancy, we identified
1193 distinct proteins with a valid primary accession
number. The combination of rigorous data validation
coupled with the removal of immunoglobulin-related
proteins for separate analysis reduced this number to 697,
which we refer to as our 'stringently validated high confi-
dence protein set'. 70 of these 697 proteins were identified
with 1 peptide (Figure 1) and 84 proteins were identified
with exactly 2 peptides. The remaining 541 proteins wereBMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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identified with 3 or more peptides. 314 proteins were
identified with 3–10 peptides and 229 proteins had 11 or
more peptides. 12 proteins were identified with over 100
peptides (Table 2). The protein identified with the highest
number of peptides was apolipoprotein B-100 (505 vali-
dated non-redundant peptides), while albumin, a protein
known to be extremely abundant in blood plasma, was
identified with 94 validated, non-redundant peptides.
The 697 validated proteins in our list [see Additional file
2] were identified with 37,682 non-validated, redundant
peptides. This was calculated by summing all of the
redundant peptides for each validated protein in our list
across all experiments. Of these peptides, 246 did not pass
our validation criteria. Note that peptides that were inval-
idated and which belonged to proteins that ultimately
failed validation were not included in this number. Our
list of 697 validated proteins was thus identified with
37,436 validated, redundant peptides. Following removal
of peptide redundancy on a per protein basis, our list of
697 validated proteins was identified with 10,145 vali-
dated, non-redundant peptides, which equates to an aver-
age of almost 14.6 validated, non-redundant peptides per
protein and a median of 6 non-redundant peptides per
protein. The number of validated, non-redundant pep-
tides was calculated by considering each protein sepa-
rately. The redundancy within each protein's peptides was
removed and the remaining peptides were summed.
Removal of the redundancy after pooling the peptides
from all validated proteins left us with 9263 valid, non-
redundant peptides. As mentioned, these numbers refer to
the dataset excluding all proteins annotated as immu-
noglobulins and proteins whose peptides mapped com-
pletely to immunoglobulin protein sequences but were
annotated as hypothetical proteins. We did not compre-
hensively examine the similarity of all protein sequences
from our validated list to immunoglobulin sequences.
If we depict the number of validated non-redundant pep-
tides versus the MW of the appropriate protein, it is very
clear that most proteins identified have a MW below 100
kDa and not more than 50 unique peptides (Figure 2). As
expected, smaller proteins tend to be identified with fewer
peptides than larger proteins. It appears that 50 peptides
are, in general, the maximum number of peptides
sequenced, even for larger proteins.
From a total of 37,682 non-validated, redundant pep-
tides, the highest proportion of peptides (3971) had a
length of 9 amino acids, followed by 3487 peptides with
11 amino acids, 3401 peptides with 10 and 3149 peptides
with 8 amino acids in length. The longest peptides
sequenced were 59 amino acids in length. 995 of the
10,145 validated, non-redundant peptides were 9 amino
acids in length, followed by 856 peptides with 10, and
852 peptides with a length of 11 amino acids. We identi-
fied a total of 749 validated, non-redundant peptides hav-
ing a length of 7 amino acids, which comprised
approximately 7.4% of 10,145 validated, non-redundant
peptides in total for the set of 697 high-confidence pro-
teins. 285 of the 697 proteins were identified with a set of
peptides among which we found at least one peptide with
a length of 7 amino acids. 324 and 365 of the 697 proteins
were identified with a set of peptides that included pep-
tides with 8 and 9 amino acids in length respectively. 184
proteins were exclusively identified with peptides ≥ 10
amino acids in length.
In Figure 3 we depicted the number of proteins versus their
MW. 346 proteins (49.6%) were identified with a MW <
45 kDa, and 351 proteins (50.4%) with a MW ≥ 45 kDa.
From those 346 proteins with a MW < 45 kDa, 6 proteins
had a MW < 10 kDa, 52 proteins had a MW of 10 ≤ MW <
15 kDa, and 288 proteins fall in the group of 15 ≤ MW <
45 kDa. Furthermore, our analysis shows that 474 pro-
Table 2: Proteins identified with more than 100 non-redundant, validated peptides.
Protein name Number of distinct, validated peptides
Apolipoprotein B-100 [Precursor] 505
Complement C3 [Precursor] variant 235
Complement C3 [Precursor] 165
Alpha-2-macroglobulin [Precursor] 164
Complement component C4B, C4B1 164
Fibronectin [Precursor], isoform 1, 3, 5, 7, 8, 9, or 10 143
Talin-1 135
Filamin A, alpha (actin binding protein 280) 117
Fibronectin 1, isoforms 3, 4 or 5, or CRA isoforms h, j, n or m 115
Fibronectin [Precursor], isoform 8 107
Complement component 4A 105
Complement C5 [Precursor] 105
After combining the experimental data for all 8 treatments described here, the number of validated, non-redundant peptides was calculated for 
each protein and the proteins having 100 or more such peptides appear in this list. The list is arranged in descending order beginning with the 
protein having the largest number of distinct, validated peptides.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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teins of the 697 identified had a MW < 60 kDa. It should
be noted that we have not considered the possibility of
molecular weight-altering post-translational modifica-
tions such as glycosylation due to the lack of comprehen-
sive protein modification data.
Proteins with a MW of <15 kDa are freely filtered in the
glomeruli; proteins up to 45 kDa are quite rapidly filtered
and proteins between 45 to 60 kDa only restrictedly.
Plasma proteins larger than 60 kDa are not filtered
through the kidney. It is worthy of note that the MW of
approximately half of our identified proteins (346, or
49.6%) allows their unrestricted clearance through kidney
filtration due to their MW < 45 kDa. In order to be
retained for an extended period in the plasma, these pro-
teins would need to be bound to larger carrier proteins or
be subject to some other retention mechanism such as the
inclusion of the protein in a complex.
Earlier we mentioned that 49.6% of the 697 identified
proteins could be easily filtered through the kidney; thus,
the 50.4% remaining proteins could possibly reside for an
extended time period in the plasma because they have a
MW larger than 45 kDa. However, having a MW > 45 kDa
doesn't necessarily make a protein an extracellular pro-
tein. Some of the proteins with a MW > 45 kDa will of
Histogram showing the number of proteins identified versus the number of validated, non-redundant peptides found for each  protein, across all experiments Figure 1
Histogram showing the number of proteins identified versus the number of validated, non-redundant peptides 
found for each protein, across all experiments. The number of validated, non-redundant peptides used to identify each 
protein was calculated and the proteins with identical numbers of peptides were plotted in the same group, indicated on the X-
axis. For example, there are a total of 70 proteins that were identified with a single peptide. The inset depicts in detail the 
number of proteins that were identified with 1–20 peptides. Proteins identified with more than 20 peptides were categorized 
into groups as indicated.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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course be cellular proteins, such as the chaperone-like
'heat shock cognate 71 kDa protein' found in our list, or a
bundling protein such as the 'alpha-actinin 1', which is
approximately 100 kDa in size. Is there congruence
between the number of extracellular proteins predicted by
GoMiner (see below) and the number predicted according
to MW? There certainly is since most true plasma proteins
have a MW above filtration cut off. However, this equa-
tion is not as precise, nor as simple as that. Not all of the
proteins that are classified as 'extracellular' and which are
not part of the 'extracellular matrix' will be plasma pro-
teins. Extracellular proteins such as heparin cofactor II or
transforming growth factor-beta induced protein IG-H3
may also be found in the extracellular space (also known
as intercellular or interstitial space). Also, some proteins
cannot be clearly classified as 'cellular' or 'extracellular',
such as uromodulin, a phosphatidylinositol-linked mem-
brane protein, which is also secreted into the urine after
cleavage. Another protein, pigment epithelium-derived
factor, is found both in retinal pigment epithelial cells and
in blood plasma.
According to GoMiner, of the 540 proteins recognized as
being part of the cellular component from our list of 697,
208 of the proteins were categorized as 'extracellular' and
392 proteins as 'cellular', although some proteins fall into
both categories. Because of this redundancy we have cho-
sen to normalize the sum of the cellular and extracellular
categories to 100% for comparison purposes; thus, 35%
of the proteins were categorized as extracellular and 65%
as cellular (Figure 4). 44 proteins from the extracellular
protein group were classified as 'extracellular matrix' pro-
teins, leaving the remaining 164 proteins from the extra-
cellular protein category as possible plasma proteins. As
Histogram depicting the number of validated, non-redundant peptides versus the MW of the identified proteins Figure 2
Histogram depicting the number of validated, non-redundant peptides versus the MW of the identified pro-
teins. The number of validated, non-redundant peptides used to identify each protein was calculated and this number was plot-
ted as a function of the molecular weight of that particular protein. The MW range (X-axis) was truncated at 550 kDa, resulting 
in the loss of one protein. Likewise, the number of validated, non-redundant peptides (Y-axis) was truncated at 250 peptides, 
resulting in the loss of an additional protein.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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for the remaining 157 proteins not categorized by GoM-
iner as cellular components, their subsequent classifica-
tion could potentially alter the present profile.
It is interesting to consider the number of proteins that
were found to have a signal peptide, since the presence of
a signal peptide indicates that a protein is normally
secreted and may thus be a 'true' plasma protein. Our soft-
ware application that made it feasible to retrieve informa-
tion based on accession number from the SwissProt/
UniProt and NCBI databases for each of our identified
proteins also facilitated deposition of signal sequence
information into our database. Overall, 44% of our list
containing 697 proteins was reported to have a signal
sequence, while in 56% of the cases there was no evidence
in the literature indicating the presence of a signal
sequence (data not shown). In the cases where a signal
sequence is not reported, this of course does not exclude
the possibility that these proteins have one. As indicated
by Swiss-Prot, NCBI and other on line data sources, the
presence of a signal sequence was either not investigated
or it could not be inferred from similar sequences. For all
of the 'hypothetical' proteins, for example, no data are
given regarding the presence or absence of a signal
sequence.
It seems reasonable to assume that the majority of the 208
proteins (35%) classified as 'extracellular' by GoMiner
should have a signal sequence. 90% (188/208) of these
extracellular proteins were indeed reported to have a sig-
nal sequence. It is unclear why the remaining 10% do not
possess one.
The fact that 32% (125/392) of the proteins classified as
'cellular' by GoMiner also have a signal sequence compli-
cates the issue further. Proteins that are localized in the
endoplasmic reticulum (ER), for example, are likely to
have a signal sequence. This is the case for calreticulin,
Histogram showing the molecular weight distribution of the calculated masses of 697 observed plasma proteins Figure 3
Histogram showing the molecular weight distribution of the calculated masses of 697 observed plasma pro-
teins. The calculated protein masses for all proteins from all experiments were categorized into molecular weight groups as 
indicated so that the number of proteins falling into each molecular weight group is proportional to the height of each bar in 
the histogram.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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which is localized in the ER lumen and is also reported to
have a signal sequence according to GoMiner and Swiss-
Prot. According to Swiss-Prot, Di-N-acetylchitobiase is a
lysosomal protein which is involved in the degradation of
asparagine-linked glycoproteins, has a signal sequence
and is categorized by GoMiner as a cellular-cytoplasm
protein.
To cloud the issue further, we mentioned that having a
MW > 45 kDa does not necessarily make a protein an
extracellular one and thus having a MW of < 45 kDa is no
guarantee that a protein is cellular. Bound to larger carrier
proteins, proteins of 45 kDa or less may well exert their
function as plasma proteins. Complement factor H-
related protein 4, which is involved in complement regu-
Pie chart representation of all validated proteins which were categorized as GO cellular component Figure 4
Pie chart representation of all validated proteins which were categorized as GO cellular component. Of the 697 
plasma proteins identified, 540 of these fell into the 'GO cellular component' category. Of the 540 'GO cellular component' 
proteins, 392 (65%) were classified as 'cellular' and 208 (35%) were classified as 'extracellular'. 44 of the proteins from the 
'extracellular' category were classified as 'extracellular matrix' proteins. Note that because some of the proteins have been 
reported more than once, the total number of proteins reported for the two categories shown is actually higher than the total 
number of proteins for the 'GO cellular component'. We have therefore normalized the sum of the cellular and extracellular 
components to 100%.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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lation and has a MW of 38.5 kDa, is expressed in the liver
and is secreted into the plasma where it was found to be
associated with lipoproteins [16] [UniProtKB/Swiss-Prot
entry Q92496]. Platelet factor 4 has a mass of ca. 11 kDa
and is bound to a proteoglycan molecule that is released
during platelet aggregation. It would be interesting to
know the correlation between the plasma protein MW
and the degree of carrier protein binding, but it is likely
that this correlation is sequence dependent and would not
be trivial to ascertain.
Without a doubt, the biggest challenge in the study of the
human plasma proteome is overcoming the detection
problems associated with its large protein concentration
range, which spans more than 10 orders of magnitude.
High abundance proteins mask the low abundance pro-
teins, making the identification of the latter extremely dif-
ficult or even impossible, using current technology.
However, both high and low abundance proteins can be
clinically meaningful and can also be the subjects of clin-
ical assays. Approximately 10 of the most abundant pro-
teins represent roughly 90% of the total protein mass in
human plasma, while another 10+ most highly abundant
proteins account for an additional 9% of the total protein
mass [17]. Hence, slightly more than 20 proteins account
for approximately 99% of the total protein mass in
plasma. We plotted all of the proteins reported by Schu-
chard et al. [17] as a function of the number of valid, non-
redundant peptides we isolated for each protein (Figure
5). We did not, however, include the immunoglobulins or
prealbumin in our analysis. We are aware that counting
peptides is not quantitative and that the molecular weight
of the proteins has an impact on this type of analysis, but
it still provides a crude estimate of the abundance of these
proteins. An estimated 10,000 proteins reside in the
remaining 1% of the plasma protein mass [18]. Among
these are proteins of very low concentration, such as hor-
mones, cytokines and tissue leakage products. For exam-
ple, two of the proteins we identified, myotrophin and C-
reactive protein, are of clinical relevance. Both are novel
cardiac biomarkers in heart failure diagnosis. Unlike acute
coronary syndromes, the definition of heart failure is a
bedside diagnosis based on clinical signs and symptoms
rather than any stand-alone test result. The use of biomar-
kers in the diagnosis and management of heart failure
may thus facilitate better clinical judgment. Myotrophin is
a small protein of about 13 kDa. It was identified with 4
valid, non-redundant peptides of 10, 13, 17 and 20 amino
acids in length. The three peptides having lengths of 10,
13 and 17 residues possess an MS3 spectrum in addition
to their MS2 Mascot scores, giving rise to scores of 70, 131
and 176 (summed score of 377), respectively. C-reactive
protein (ca. 25 kDa) occurs in plasma at concentrations of
6.8 – 820 × 10-8 g/ml [19] and is several orders of magni-
tude less in concentration than abundant proteins such as
serum albumin, which is found at a concentration of 3.5
– 5.2 × 10-2 g/ml (Table 3). It was identified with 8 valid,
non-redundant peptides of 7, 8, 10 (2 × 10 mers), 11 (2 ×
12 mers), 12 and 15 amino acids in length, with MS2 or
MS3 scores of 135, 39, 123, 104, 115, 35 (no MS3), 116,
and 35 (no MS3) respectively, and a summed score of
702. Despite their low abundance and small MW, the cor-
rect identifications of both of these proteins were made
with high confidence [see Additional file 2].
The LTQ-FT and oribitrap mass spectrometers that we
employed in this study can be considered to be cutting
edge technology when it comes to mass spectrometry.
However, despite the extremely high dynamic range cov-
ered by these instruments, the overall plasma protein con-
centration range currently resolvable is only up to 7 orders
of magnitude (Table 3). We seem to be able to compre-
hensively cover up to about 4 orders of magnitude.
Beyond this the detection of a protein is not guaranteed
and indeed, the less abundant a protein is and the smaller
its MW, the more unlikely is its detection. However, the
unprocessed precursor of anti-hemophilic factor (coagu-
lation factor VIII) was not detected despite its large MW of
267 kDa. At the same time, proteins that are 1 to 2 orders
of magnitude less abundant and with much smaller MW,
such as C-reactive protein and myotrophin, could be con-
clusively identified.
As to the content of our high confidence set of 697 pro-
teins, which excludes immunoglobulins, a simple query
of the BPPD revealed the identification of 30 proteins that
are annotated as 'hypothetical' and 31 that are annotated
as 'keratin'. 13 proteins are annotated as 'kinase' and 16
proteins as 'growth factor' [see Additional file 2]. Based on
their annotation and/or tissue specificity and subcellular
location, 66 proteins are readily identifiable as true
'plasma' proteins (not plasma membrane).
Furthermore, we have provided a short selection of pro-
teins that have important biological function(s) and/or
have some role in a disease process (Table 4).
Comparison of individual experiments
All of the protein validation rules that we applied to the
combined set of 697 proteins were also applied to each
individual experimental dataset before comparison. In the
course of analysing the data from the different experimen-
tal treatments listed in Table 1, we noted some interesting
observations. In performing the comparisons, we looked
at the total number of proteins identified and those found
to be in common between experiment pairs (Figure 6).
Furthermore, the valid, non-redundant peptide distribu-
tion vs. proteins identified (Figure 7), as well as the MW
distributions (Figure 8) for the different experiments were
investigated.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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In order to determine whether choosing restricted precur-
sor selection would affect our identification of proteins
from samples, we compared the results of 01_MS2 and
04_MS2_prec (Figure 6, panel A). Interestingly, there were
only 16 proteins that were identified in 04_MS2_prec that
were not identified in 01_MS2. Even though more plasma
sample was applied to the 1D PAGE gel in experiment
04_MS2_prec, significantly more proteins were identified
in 01_MS2. Additionally, 04_MS2_prec was the experi-
mental protocol that identified the least number of pro-
teins of any of the experiments, suggesting that several
hundred more μg of protein could not make up for the
seemingly disadvantageous MS setting of restricted pre-
cursor selection chosen for 04_MS2_prec. Note that single
peptide identifications do not appear in 01_MS2 and
04_MS2_prec because our validation criteria demanded
an MS3 spectrum, which is precluded in these experi-
ments which were only MS2-based (Figure 7, panels A and
B). We also plotted the molecular weight distribution of
the proteins identified in 01_MS2 (Figure 8, panel A) and
04_MS2_prec (Figure 8, panel B) and found that many of
the additional proteins identified in 01_MS2 fell into the
15–45 kDa range.
In order to determine the effect of the amount of plasma
protein loaded on the gel with respect to the number of
proteins identified, we performed a comparison between
01_MS2 and 05 (Figure 6, panel B). We identified 166
proteins in 01_MS2 and 228 proteins in 05 but because
there are two variables involved in this comparison
(namely protein loading and collection of MS3 data), we
eliminated single peptide identifications from experiment
05 in order to negate the MS3 variable. This left us with
197 proteins identified in 05 (without MS3) and 166 pro-
teins identified in 01_MS2. Since we loaded about 300 ug
more protein (67%) in 05 compared to 01_MS2, the iden-
tification of more proteins in 05 doesn't seem surprising.
However, it should be noted that the extra protein loaded
in 05 resulted in only 19% more proteins identified com-
pared to experiment 01_MS2.
Table 3: Plasma protein concentration ranges of selected proteins.
Plasma protein Known protein concentrations (g/ml) Distinct peptides Mass (Da)
Serum albumin 3.5 – 5.2 × 10-2 94 69367
Fibrinogen (alpha chain) 2.0 – 4.0 × 10-3 96 94973
Alpha-2-macroglobulin (male adult) 0.9 – 4.0 × 10-3 164 163278
Alpha-1-antitrypsin 7.8 – 20 × 10-4 44 46737
Haptoglobin 3.0 – 22 × 10-4 52 45205
Transthyretin, Thyroxine-binding prealbumin 2.8 – 3.5 × 10-4 19 15887
Ceruloplasmin 1.5 – 6.0 × 10-4 95 122205
Prothrombin 1.0 × 10-4 53 70037
Fletcher factor (Plasma kallikrein precursor) 5.0 × 10-5 37 71370
Complement component C6 4.8 – 6.4 × 10-5 61 104844
Complement component C9 4.7 – 6.9 × 10-5 32 63174
Hageman factor (Coagulation factor XII) 2.9 × 10-5 27 67818
Complement C1r component 2.5 – 3.8 × 10-5 45 80174
Properdin (Factor P) 2.4 – 3.2 × 10-5 25 1 2 7 6
Complement C2 2.2 – 3.4 × 10-5 45 83268
Von Willebrand factor 7 × 10-6 55 309299
Stuart factor (Coagulation factor X) 5.0 × 10-6 18 54732
Christmas factor (Coagulation factor IX) 4.0 × 10-6 16 51748
Transferrin soluble receptor (adult), Serotransferrin 0.8 – 1.8 × 10-6 89 77050
Proconvertin (Coagulation factor VII) 1.0 × 10-6 *5 3 0 4 3
Mannose-binding protein C (MBP) 0.3 – 4.1 × 10-6 14 26144
Beta-2-microglobulin 8.0 – 24 × 10-7 81 3 7 1 5
Antihemophilic factor (Coagulation factor VIII) 1.0 × 10-7 --- 267009
C-reactive protein, splice isoform 1 6.8 – 820 × 10-8 82 5 0 3 9
Insulin-like growth factor II 9.9 – 50 × 10-8 52 0 1 4 0
Myoglobin 6.0 – 85 × 10-9 41 7 0 5 3
Prolactin (male), awake 1.0 – 7.0 × 10-9 --- 25876
Insulin 2.0 – 8.4 × 10-10 --- 11981
Included in the table are proteins identified in our high confidence set of plasma proteins that represent a wide range of protein molecular weights 
and which have known plasma protein concentrations. Also included are some proteins that are known to be of higher abundance, but which were 
not detected in our experiments, and these were included to demonstrate that fact. The protein name, known plasma protein concentration, the 
number of unique peptides identifying the protein, the summed Mascot score and the MW is shown and the table has been sorted in descending 
order with the protein possessing the highest known protein concentration listed first.
--- indicates that this entry was not identified in this study.
* indicates that this entry was identified but not validated.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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The utilization of more applied protein and MS3 in 05 ver-
sus 01_MS2 did not have an appreciable impact on the
profile depicting unique peptide distribution (Figure 7,
panels A and C) except for the single peptide peak due to
MS3. The MW distributions of the identified proteins in
05 and 01_MS2 (Figure 8, panels C and A respectively)
appear highly similar and are unaffected by the removal of
proteins identified with a single peptide since the addi-
tional proteins identified in 05 are found to be equally
distributed across all MW ranges.
In order to examine the effect of protease inhibitor addi-
tion to plasma samples, we compared experiment
06_Alb_depl with 10_Alb_depl_NL where we obtained
337 vs 258 proteins identified respectively (Figure 6,
panel C). Because the MS3 settings for these experiments
were different (neutral loss-dependent MS3 was used in
this study in experiment 10_Alb_depl_NL only) we
negated the MS3 results by removing single peptide-based
protein identifications from both experiments, thus
allowing a comparison based only on the addition of pro-
tease inhibitors. Removal of single peptide identifications
left us with 299 proteins identified in 06_Alb_depl and
251 proteins identified in 10_Alb_depl_NL. In our hands,
the addition of protease inhibitors (10_Alb_depl_NL) did
not result in identifying more proteins, but rather we
obtained 48 fewer proteins than in 06_Alb_depl.
Neutral loss-dependent MS3 detects the loss of phos-
phoric acid (ca. 98 Da) from the precursor ion in a MS2
Pie chart representation of the 21 most highly abundant plasma proteins from our set of 697 proteins across all experiments Figure 5
Pie chart representation of the 21 most highly abundant plasma proteins from our set of 697 proteins across 
all experiments. 10 of the 21 most highly abundant plasma proteins from our analysis are depicted in the pie chart. The small 
table to the right of the pie chart contains the next 11 most abundant proteins. The size of each pie piece is proportional to the 
number of unique peptides that we sequenced for that particular protein, relative to the total number of peptides for all 21 
proteins depicted.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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Table 4: Selected proteins and their possible involvement in diseases.
Accession MW Protein name Function Disease
Q15848 26414 Adiponectin Hematopoiesis, immune system; fat metabolism
and insulin sensitivity.
Adiponectin deficiency; obesity 
insulin resistance, diabetes type 2.
P37840 14460 Alpha-synuclein, isoform 1, 2, or 3 Regulation of dopamine release and transport.
Decreased caspase 3 activation.
Defects in SNCA cause autosomal
dominant Parkinson disease 1 and
Lewy body dementia (DLB).
P02741-1 25039 C-reactive protein, splice 
isoform 1
Enhances host defense. Inflammation, heart disease 
biomarker.
P06703 10180 Calcyclin (Prolactin receptor 
associated protein)
Preferentially expressed during quiescent 
fibroblast 
proliferation.
It is inducible by growth factors
and overexpressed in acute
myeloid leukemias
P31944 27680 Caspase-14 Apoptosis.
P07339 44552 Cathepsin D Acid protease active in intracellular 
protein breakdown.
Disease pathogenesis: 
breast cancer, possibly 
Alzheimer's disease.
P81605 11284 Dermcidin Neuron survival; phosphatase and antimicrobial
activity.
Q99497 19891 DJ-1 protein (Oncogene DJ1) Androgen receptor-dependent transcription
regulator; prevents aggregation of SNCA; 
protects
neurons from oxidative stress and cell death; 
role
in fertilization.
Early-onset Parkinson disease 7 
(PARK7).
P23142-1 77261 Fibulin-1, splice isoform 1 or D Cell adhesion/migration, organization of ECM,
haemostasis and thrombosis, modulation of APP,
tumor suppressor.
human breast cancer;
synpolydactyly (limb malformation)
P23142-4 74462 Fibulin-1, splice isoform 4 or C human breast cancer; does not 
seem to be implicated in 
synpolydactyly
O75636-1 32903 Ficolin 3, splice isoform 1 Lectin activity. Systemic lupus erythematosus
(SLE).
P16930 46374 Fumarylacetoacetase Not found Defects in FAH are the cause of 
tyrosinemia type I.
Q7M4S4 2046 Granulocyte inhibitory protein Inhibits the biological activity of 
polymorphonuclear
 cells.
P01344-1 20140 Insulin-like growth factor II, 
splice isoform 1
Growth-promoting activity; fetal development.
P05362 57826 Intercellular adhesion molecule-1 ICAM proteins are ligands for the leukocyte 
adhesion LFA-1 protein (Integrin 
alpha-L/beta-2).
P13473 44961 Lysosome-associated membrane
glycoprotein 2, splice isoform 1 or
2
Lysosomal maintenance; intracellular signal 
transduction.
Implicated in tumor cell metastasis.
P02144 17053 Myoglobin Reserve O2 supply, O2 movement within muscles.
P58546 12764 Myotrophin Cerebellar morphogenesis. Seems to be associated with 
cardiac hypertrophy.
P22392 17401 NM23-LV (contains Nucleoside 
diphosphate kinase B sequence)
Nucleoside diphosphate kinase B is a  
transcriptional activator of the c-Myc gene; 
binds DNA nonspecifically.
Reduced amounts of Nucleoside  
diphosphate kinase B in tumor cells
of high metastatic potential.
P15531 17149 Nucleoside diphosphate kinase A Synthesis of nucleoside triphosphates other than 
ATP.
Neuroblastoma.
P10720 10845 Platelet factor 4 variant Inhibitor of angiogenesis, endothelial cell 
chemotaxis.
P01133 133946 Pro-epidermal growth factor Growth of epidermal and epithelial tissues.
P27918 51276 Properdin (Factor P) Alternate complement pathway; binds C3- and 
C5-
convertase enzyme complexes.
Properdin deficiency (PFD); higher  
susceptibility to bacterial infections;
especially meningococcal.
P61019 23546 Ras-related protein Rab-2A Protein transport; endoplasmic reticulum to 
Golgi 
complex.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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scan and initiates MS3 fragmentation analysis of the neu-
tral loss precursor ion. As expected, the use of this method
reduced the number of proteins with 1 peptide (Figure 7,
panels D and E), which is also reflected in the lower
number of proteins with smaller MW (< 45 kDa) (Figure
8, panels D and E). Although the neutral loss-dependent
MS3 setting used in experiment 10_Alb_depl_NL was
employed to detect phosphopeptides, the results obtained
were unclear and therefore are not reported here.
To determine the effect of protein depletion on the
number of proteins identified, a somewhat different
approach was used, and different results were seen for
08_OGE and 09_OGE_6_depl (Figure 6, panel D). Both
experiments employed OGE separation, while
P51149 23490 Ras-related protein Rab-7 Protein transport. Vesicular traffic. Charcot-Marie-Tooth disease type 
2B (CMT2B).
Q12913 145927 Receptor-type tyrosine-protein 
phosphatase eta
Mechanism of contact inhibition of cell growth. Cancers of colon, lung, and breast.
P48594 44854 Squamous cell carcinoma antigen 
2
Protease inhibitor; host immune response 
modulator.
Seems to also be secreted in  
plasma by cancerous cells but at a
low level.
Q15582 74681 Transforming growth factor-beta 
induced protein IG-H3
Cell-collagen interactions; endochondral bone 
formation.
Corneal dystrophy Groenouw type 
I (CDGG1).
P07911 69761 Uromodulin Not known. Possible regulation of cytokines. Familial juvenile hyperuricemic 
nephropathy (HNFJ); medullary 
cystic kidney disease 2 (MCKD2).
We have provided a short selection of proteins that we identified in our experiments and that have important biological functions and/or may have 
some role in a disease process. The table includes a description of the protein function, the disease involved, the primary accession number of the 
protein, and the molecular weight and name of the protein and has been arranged alphabetically according to protein name.
Table 4: Selected proteins and their possible involvement in diseases. (Continued)
Venn diagram representations of comparisons between pairs of individual plasma experiments Figure 6
Venn diagram representations of comparisons between pairs of individual plasma experiments. Individual exper-
iments are represented by circles, with compared experiment pairs being depicted by overlapping sets of two circles. The 
number of proteins identified in both members of a compared set of experiments is given in the intersection region of the cir-
cles. The number of proteins that are unique to an individual experiment is shown outside of the intersection region, along 
with the total number of proteins identified for that individual experiment, shown in parentheses. The plasma experiment rep-
resented by each circle is represented at the top of the respective circle, outside of the intersection region (panel A, for exam-
ple, shows a comparison of experiments 01_MS2, designated "01'', and 04_MS2_prec, designated "04''). The experimental 
conditions used in each experiment can be found in Table 1. Panel F shows a comparison between all 7 experiments performed 
on the FT and the last experiment which was performed on the Orbitrap.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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Histograms showing the number of proteins identified with a given number of unique peptides for each individual experiment Figure 7
Histograms showing the number of proteins identified with a given number of unique peptides for each indi-
vidual experiment. The number of validated, non-redundant peptides was calculated for each protein identified within the 
context of each individual experiment, and proteins having identical numbers of peptides were grouped together and plotted as 
indicated. The Y-axes (number of proteins) for the experiments indicated in panels C and D and in A, B, E, F and G have been 
standardized in order to facilitate cross-experiment comparison.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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Histograms depicting the molecular weight distribution of the identified proteins in each of the 8 experiments Figure 8
Histograms depicting the molecular weight distribution of the identified proteins in each of the 8 experiments. 
The proteins from each individual experiment were grouped according to their calculated molecular weight and plotted as indi-
cated. All Y-axis scales except for the ones in panels D and H have been standardized to facilitate cross-experiment compari-
son.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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09_OGE_6_depl was additionally depleted of six high
abundance proteins, including albumin, transferrin, hap-
toglobin, alpha-1-antitrypsin, IgA and IgG. Since the
immuno-depletion column employed removes from
approximately 65% to 85% of the total plasma protein
(Agilent, personal communication; [20]), the amount of
protein loaded in the 09_OGE_6_depl_sample was corre-
spondingly reduced to 650 ug to compensate for the load-
ing of the non-depleted 1800 ug from 08_OGE. We found
that experiment 09_OGE_6_depl produced more vali-
dated proteins than 08_OGE (Figure 6, panel D), suggest-
ing that the depletion step may have been somewhat
advantageous. The majority of the additional 47 proteins
in 09_OGE_6_depl as compared to 08_OGE were identi-
fied with up to 10 peptides (Figure 7, panels G and F
respectively), and can be found mostly in the lower MW
range of up to 45 kDa (Figure 8, panels G and F respec-
tively), supporting the idea that depletion may facilitate
the identification of otherwise 'overshadowed' smaller
proteins.
In order to compare the 1D-PAGE and OGE separation
methods, we performed two experiments, 05 and
08_OGE, neither of which employed a depletion step.
Even though 2.4 times more protein was loaded in
08_OGE, more proteins were identified in the 05 experi-
ment (Figure 6, panel E). This suggested that in our hands
the 1D-PAGE separation seemed to be more effective than
the OGE technique.
Experiment 05 (Figure 7, panel C) identified twice as
many proteins with 1 peptide and more proteins with 2
peptides than 08_OGE (Figure 7, panel F). With respect to
the MW distribution, experiment 05 had 1.7 times more
proteins with a MW of up to 45 kDa than 08_OGE (Figure
8, panels C and F). These observations support the notion
that plasma separation by OGE rather than by 1D PAGE
may thus adversely affect the identification of proteins of
low abundance and/or in the small MW range.
Finally, a comparison between the data obtained from all
7 plasma gels analysed on the FT with the results from
experiment 11_Orbitrap (Table 1), which was analysed
via the Orbitrap confirm that the Orbitrap is a high per-
formance mass spectrometer. Even though significantly
less plasma sample was applied to the Orbitrap compared
with the 7 samples measured on the FT, the results of both
analyses are comparable. Both instruments yielded about
500 high confidence proteins and 332 (ca. 65%) identical
protein identifications (Figure 6, panel F). Also, as seen on
Figure 7, panel H, none of the 510 proteins identified on
the Orbitrap was validated with only one peptide (MS3
was not performed), whereas 93 proteins from the 495
identified collectively by all FT runs were validated with 1
peptide using MS3. Figure 8, panel H shows that the MW
distribution for the Orbitrap data is quite similar to the
data obtained in several of the FT experiments, notably
06_Alb_depl (Figure 8, panel D) and 10_Alb_depl_NL
(Figure 8, panel E). The serum samples were depleted
prior to MS analysis in all three experiments.
In comparing individual experimental results, the expec-
tation is that proteins of higher molecular weight and/or
higher abundance should have a higher likelihood of
being identified across experiments due to the associated
higher probability of isolating and identifying peptides
from those two groups of proteins. Although we did not
have comprehensive data available to us concerning pro-
tein abundance, we thought it would still be interesting to
know whether the common proteins identified in a given
set of experiments favor a certain MW range. Figure 9,
panel A illustrates the MW distribution of the 332 pro-
teins that were identified by both the FT and the Orbitrap.
This histogram profile is very similar to the one depicting
the MW distribution of all 510 proteins isolated using the
Orbitrap (Figure 8, panel H) and also to the profile gener-
ated by plotting the MW data from all seven FT-based
experiments (not shown). Since we used what we consid-
ered to be the best plasma handling method (depletion/
1D-PAGE) for the Orbitrap experiment, it came to us as
no surprise that the MW profile of the shared 332 proteins
isolated using the FT and Orbitrap should produce similar
MW profiles. In contrast to this, a comparison of all indi-
vidual experiments to each other produced a set of only
56 proteins identified across all experiments. In this case
the MW profile of the proteins found across all experi-
ments shows a definite bias toward proteins of higher
molecular weight, as expected (Figure 9, panel B). Almost
all of these 56 proteins are classical plasma proteins, exert-
ing their function within the plasma (Table 5). The low
numbers of shared proteins between all experiments high-
lights the high variability in protein identification seen
when using different methods and instruments in MS-
based proteomic analysis.
Despite everything, many proteins (Table 4) would not
have been identified if not for the use of plasma depletion
techniques. For example, the smallest protein identified
'Granulocyte inhibitory protein' (2045 Da), was identi-
fied in 06_Alb_depl, and another protein of 11 kDa (der-
mcidin) was identified in 09_OGE_6_depl and
11_Orbitrap only. In fact, myotrophin (13 kDa) was iden-
tified in all four experiments where we employed deple-
tion (06_Alb_depl, 09_OGE_6_depl, 10_Alb_depl_NL
and 11_Orbitrap), but in no other experiment. In sum-
mary, it seems reasonable to recommend plasma deple-
tion as a method to facilitate the identification of lower
MW and lower abundance proteins. When the seven
experiments measured on the FT are compared, the high-
est proportion of proteins listed in additional file 2 [seeBMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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Table 5: List of the 56 proteins found in all 8 experiments.
Primary accession 
number
IPI number (version 3.25) Protein 
MW
Protein name
P43652 IPI00019943 69069 Afamin [Precursor]
P02763 IPI00022429 23512 Alpha-1-acid glycoprotein 1 precursor
P19652 IPI00020091 23603 Alpha-1-acid glycoprotein 2 [Precursor]
P01011 IPI00431656/IPI00550991/IPI00411920 47651 Alpha-1-antichymotrypsin [Precursor]
P04217 IPI00022895/IPI00644018 54273 Alpha-1B-glycoprotein [Precursor]
P02765 IPI00022431 39325 Alpha-2-HS-glycoprotein [Precursor]
P01023 IPI00478003 163278 Alpha-2-macroglobulin [Precursor]
P02760 IPI00022426 39000 AMBP protein [Precursor]
P01008 IPI00032179 52603 Antithrombin-III [Precursor]
P02647 IPI00021841 30778 Apolipoprotein A-I [Precursor]
P02652 IPI00021854/IPI00382587 11175 Apolipoprotein A-II [Precursor]
ENSP00000350425 IPI00304273 45399 Apolipoprotein A-IV [Precursor] (Apo-AIV)
P04114 IPI00022229 515563 Apolipoprotein B-100 [Precursor]
P02655 IPI00021856 11284 Apolipoprotein C-II precursor
P02656 IPI00021857/IPI00657670 10852 Apolipoprotein C-III [Precursor]
P05090 IPI00006662 21276 Apolipoprotein D [Precursor]
P02649 IPI00021842 36154 Apolipoprotein E [Precursor]
O14791-2 IPI00514475/IPI00186903 45871 Apolipoprotein-L1 [Precursor], splice isoform 2
P04003 IPI00021727 67033 C4b-binding protein alpha chain [Precursor]
P00450 IPI00017601 122205 Ceruloplasmin [Precursor]
P10909 IPI00291262 52495 Clusterin [Precursor]
P00748 IPI00019581 67818 Coagulation factor XII [Precursor] (Hageman factor)
P02747 IPI00022394 25774 Complement C1q subcomponent, C chain [Precursor]
P09871 IPI00017696 76685 Complement C1s subcomponent [Precursor]
P06681 IPI00303963 83268 Complement C2 [Precursor]
P01031 IPI00032291/IPI00169407 188331 Complement C5 [Precursor]
P13671 IPI00009920 104844 Complement component C6 [Precursor]
P00751-1 IPI00019591 85533 Complement factor B [Precursor], Splice isoform 1
P08603-1 IPI00029739 139071 Complement factor H [Precursor], splice isoform 1
P02671-1 IPI00021885 94973 Fibrinogen alpha chain [Precursor] (Fibrinogen alpha/alpha-E chain precursor), 
Splice isoform Alpha-E
P02675 IPI00298497 55928 Fibrinogen beta chain [Precursor]
P02679-2 IPI00021891/IPI00167009/IPI00219713 49496 Fibrinogen gamma chain [Precursor], splice isoform 2 (isoform Gamma-A)
P06396 IPI00026314/IPI00377087 85698 Gelsolin [Precursor], plasma (Actin-depolymerizing factor)
P00738 IPI00478493/IPI00641737/IPI00431645 45205 Haptoglobin [Precursor]
P02790 IPI00022488 51676 Hemopexin [Precursor]
P05546 IPI00292950 57071 Heparin cofactor II [Precursor]
P04196 IPI00022371 59579 Histidine-rich glycoprotein [Precursor]
Q3B7H5 IPI00028413 99849 Inter-alpha (Globulin) inhibitor H3 – Homo sapiens (Human).
P19827 IPI00292530/IPI00383338 101389 Inter-alpha-trypsin inhibitor heavy chain H1 [Precursor] (ITI heavy chain H1) 
(Inter-alpha-inhibitor heavy chain 1) (Inter-alpha-trypsin inhibitor complex 
component III) (Serum-derived hyaluronan-associated protein) (SHAP)
P19823 IPI00305461/IPI00289083 106436 Inter-alpha-trypsin inhibitor heavy chain H2 [Precursor]
NP_000412 IPI00009865 58827 keratin 10 [Homo sapiens]
NP_000217 IPI00019359 62064 Keratin, type I cytoskeletal 9 (Keratin-9)
NP_006112 IPI00220327 66067 Keratin, type II cytoskeletal 1 
(Keratin-1, Cytokeratin 1; hair alpha protein)
P03952 IPI00654888 71370 Plasma kallikrein [Precursor] (Fletcher factor)
P05155 IPI00291866 55154 Plasma protease C1 inhibitor precursor
P02753 IPI00022420 23010 Plasma retinol-binding protein [Precursor]
P00747 IPI00019580 90569 Plasminogen [Precursor]
P00734 IPI00019568/IPI00006618 70037 Prothrombin [Precursor] (EC 3.4.21.5)
P02768 IPI00022434/IPI00745872 69367 Serum albumin [Precursor], splice isoform 1
P02743 IPI00022391 25387 Serum amyloid P-component [Precursor]
Q9Y490 IPI00298994 269767 Talin-1
P07996 IPI00296099 129413 Thrombospondin-1 [Precursor]
P02766 IPI00022432 15887 Transthyretin [Precursor]
ENSP00000273951 IPI00555812/IPI00742696 52918 Vitamin D-binding protein precursor
P04004 IPI00298971 54306 Vitronectin [Precursor]
P04275 IPI00023014 309299 Von Willebrand factor [Precursor]
The table provides the primary accession number, IPI number(s), protein annotation and the molecular weight of all 56 proteins that we found to be in 
common among our eight different experiments and is sorted alphabetically according to protein name.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
Page 21 of 28
(page number not for citation purposes)
Additional file 2] as well as in Table 4 originated from
experiment 06_Alb_depl. When we employed an instru-
ment having a higher sensitivity (Orbitrap), even though
much less blood plasma sample was analysed, more pro-
teins were identified. In general, the 1D-PAGE method in
combination with serum depletion and if possible, analy-
sis on a high sensitivity instrument such as the Orbitrap,
provided the most comprehensive analysis in our hands.
Discussion
Here we discuss our findings in comparison to the results
from HUPO PPP, Anderson et al and others.
Statistics
We identified 697 proteins with very high confidence, 70
proteins of those were identified with only 1 peptide
(10%) and 627 proteins with 2 or more peptides (90%).
84 proteins (12%) were identified with exactly 2 peptides,
84 (12%) with exactly 3, 51 (7%) with exactly 4, and 408
proteins (59%) with more than 4 peptides. The combined
effort of 35 laboratories, a Bioinformatics group devoted
to the PPP, and a rigorous statistical approach, combined
with multiple hypothesis testing, led to a reduced set of
889 proteins. For comparison purposes, we removed all
proteins that were annotated as immunoglobulins from
the HUPO list (94) to obtain a list of 795 remaining high
confidence proteins. Of these 795 proteins that were clas-
sified as 'high confidence HUPO proteins', 241 were iden-
tified with only 1 peptide (30%) and thus 554 with 2 or
more peptides (70%). 131 (16%) were identified with
exactly 2 peptides, 77 (10%) with exactly 3 peptides and
46 (6%) with exactly 4 peptides. 300 proteins (38%) were
identified with more than 4 peptides.
The HUPO endeavor yielded 795 proteins, while our
efforts produced 697 proteins, both lists excluding immu-
noglobulins and rated as 'high confidence'. We believe
that the protein/peptide relation of our dataset is quite
good, with 697 proteins identified by 10,145 distinct,
valid peptides, which calculates to approximately 14.6
peptides per protein on average (14.56) with a median of
6 peptides per protein identified and an overall confi-
dence level of better than 99%. The HUPO high confi-
dence set has a protein/peptide relation with 8942
peptides for 795 proteins, which is equivalent to 11 pep-
tides per protein on average (11.25), with a minimum of
95% confidence. Chan et al. [21] report the identification
of 1444 proteins with 2646 peptides. This calculates to
only 1.83 peptides per protein on average and accord-
ingly, their overall confidence level was found to be just
90%. It therefore follows that low protein/peptide rela-
tions considerably impair the confidence in a dataset.
Data validation and confidence
Adamski et al. [22] employed a Poisson model to assess a
confidence value for protein identifications that they then
applied to the HUPO PPP data set. They suggest that of the
proteins identified with one peptide, at least 70% are false
positives, while 15–30% of proteins identified with
exactly two peptides are likely to be false positives. Only
about 2–5% of the proteins identified with exactly three
peptides are likely to be false. This very high false positive
rate is acknowledged by Omenn et al. to be a major prob-
lem, especially for identifications based on 1 peptide [5].
Our validation criteria were extremely stringent and only
peptides that passed all criteria were included in the pro-
tein identification process. In fact, to the best of our
knowledge, our set of blood plasma proteins was gener-
ated according to the most stringent validation and redun-
dancy criteria published so far. Because the accuracy of
protein identification increases with peptide length, we
excluded, for example, all peptides that did not have the
minimum required length of 7 amino acids, while Adam-
ski et al. eliminated all peptides shorter than 6 amino
acids from further analysis [17]. We were also aware of the
high risk of incorrect protein identification based on 1
peptide. We therefore discarded all protein identifications
based on 1 peptide unless a given peptide was validated
by a MS3 spectrum, significantly increasing confidence in
peptide identification [7]. Additionally, it was mandatory
that the MS3 score have a confidence level of 99.9%.
Accordingly, we discarded all identifications based on 1
peptide in assays 01_MS2, 04_MS2_prec and 11_Orbitrap
since we did not employ any MS3 in these three experi-
ments. Probabilities of 99% and 95% for the first and sec-
ond peptide, respectively, were used for protein
identification with two peptides, and a minimum of 99%
probability for one of three peptides was used for identifi-
cations with three peptides. Our decoy database analysis
revealed a very low false peptide identification rate of only
0.29 percent across all of our experimental data, reinforc-
ing the notion that the use of such stringent validation cri-
teria produces high confidence data.
Compared with the PPP dataset generated by the collabo-
rative effort of 35 laboratories, our list of identified pro-
teins was not expected to be as extensive. However,
because our data were acquired using only two instru-
ments and a single search algorithm (Mascot), and
because each peptide was validated identically using the
highly stringent criteria, our data were validated homoge-
neously across all experiments performed. Thus, the huge
task of heterogeneous data integration performed by the
HUPO Bioinformatics hub was not the key challenge in
our case. Yet, the exceptionally careful removal of redun-
dancy which we performed was an incredibly time con-
suming undertaking. We feel that the strength of our
dataset lies in the superior performance of our mass spec-
trometers and their high mass accuracy, the stringency of
our validation criteria, and the homogenous manner in
which our data were collected and validated. ValidationBMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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Histograms showing the molecular weight distribution of shared proteins Figure 9
Histograms showing the molecular weight distribution of shared proteins. The calculated molecular weights of the 
proteins determined to be in common between each set of indicated experiments were categorized and plotted. Panel A 
depicts a comparison of the proteins found to be in common between the FT (seven independent experiments) and the Orbi-
trap. Panel B shows the calculated molecular weights from the 56 proteins identified in all experimental approaches.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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was performed manually and was later corroborated with
the aid of a software script and by database querying.
Importantly, data validation was carried out with meticu-
lous accuracy.
The PPP dataset was collected using low and high per-
formance mass spectrometers including LCQs, LTQs,
QTOFS, QSTARS and also an FT-ICR by one laboratory,
and was processed using different searching algorithms
such as Mascot and Sequest. While each mass spectrome-
ter and search engine has its strengths and thus the use of
these various technologies could be considered an advan-
tage in the identification process of a diverse proteome
such as the plasma proteome, the use of multiple technol-
ogies also introduces variables which must be carefully
controlled if the data are to be meaningfully compared
and/or combined. In our opinion, it is critical that the
peptide validation criteria employed for the evaluation of
different datasets be homogeneous. Although some inte-
gration features were applied to the PPP dataset, no equiv-
alency rules were applied across the search algorithms or
for the various 'high confidence' cutpoints [5]. Accord-
ingly, peptide identification was very subjective and pep-
tides of low confidence with lower probability scores were
included in protein identifications. This heterogeneity has
likely contributed to the high false positive rate of protein
identification as described by Adamski, especially for pro-
tein identifications based on one peptide.
Data comparison
In the course of comparing our data with the HUPO data
we observed that even though all HUPO proteins have IPI
numbers from version 2.21, the high confidence set of
795 proteins (without immunoglobulins) has 319 entries
that are missing cross reference information to other data-
bases such as SwissProt/UniProt, making a comparison
using this information difficult. Since the IPI datasets
change occasionally, we decided to convert all of the
HUPO data as well as our data to version 3.25 of the IPI
database in order to facilitate a comparison.
A comparison using the converted IPI numbers revealed
that 242 of our 697 high confidence proteins matched the
HUPO high confidence list, excluding immunoglobulins.
However, several circumstances make it likely that this
number is not 100% precise. First, we discovered exam-
ples of annotations in the HUPO list that are not com-
pletely accurate, as well as examples of redundant entries
(see below). Second, we verified that our peptides
matched the protein sequences referenced by the primary
accession number (SwissProt, RefSeq, Ensemble or H-
INV), but we did not do this for the IPI numbers that were
assigned by Mascot, so we cannot assure a 100% correct
assignment of our proteins and peptides to the indicated
IPI numbers. However, the 242 matching entries gave us
a reasonable measure of the extent of matching proteins
from the two datasets without claiming a 100% accurate
comparison.
Redundancy
In the course of our analysis of the HUPO high confidence
set we encountered some protein identifications having
identical SwissProt and/or IPI accession numbers that
appeared to be duplicates. For example, we found that the
SwissProt accession numbers P01024, P22792, and
Q8N355 each occur twice, while 13 different IPI numbers
each appeared twice (data not shown). Visual inspection
of the annotations for these entries indicated to us that it
may have been appropriate to merge many of the dupli-
cate entries.
There were other entries in the HUPO list that seemed to
be redundant even though they had distinct IPI numbers
and distinct annotations. In the HUPO list, IPI00293665
(P04259) is annotated as "Keratin type II cytoskeletal 6B",
while IPI00296350 (P48669) is annotated as "Keratin
type II cytoskeletal 6F". Upon further investigation, we
found that according to the EBI, both IPI00293665 and
IPI00296350 refer to "Keratin type II cytoskeletal 6B".
In another example, the 7 distinct peptides listed in
HUPO's PPP for IPI00293057 (HUPO annotation "car-
boxypeptidase b-like protein") are also found in the
sequence IPI00329775 (HUPO annotation "carbox-
ypeptidase b2"). All 13 of the distinct HUPO peptides
listed for IPI00329775 map to the sequence for
IPI00329775, but 4/13 peptides do not map to the
IPI00293057 sequence. Our observations indicate that
these entries should be collapsed into one entry,
IPI00329775, since there are no peptides that unambigu-
ously identify IPI00293057.
Care must also be taken in correctly annotating isoforms.
For example, the HUPO set identifies ADP-ribosylation
factor 3 (IPI00215917). However, the single peptide used
to identify this protein also maps to ADP-ribosylation fac-
tor 1 (IPI00215914) and the correct annotation should
therefore be ADP-ribosylation factor 1 or 3. In a last exam-
ple, HUPO lists 76 distinct peptides identifying alpha-1-
antichymotrypsin isoform 2 (IPI00032215). Upon closer
inspection, 35 of the 76 peptides did not match isoform
2, but all 76 of the peptides were found to match alpha-1-
antichymotrypsin isoform 1 instead (IPI00550991).
The examples of inaccuracy and redundancy that we iden-
tified within the HUPO high confidence list (above) make
it evident that much effort is needed to ensure the accu-
racy of a data set such as we present here. Given that the
public databases are in a constant state of flux, disparities
in the data, such as those we have listed above, could atBMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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least partially be the result of changes to records in the
parent databases over time. Unfortunately, search engines
like Mascot, Sequest, PepSea or Sonar are not currently
'sophisticated' enough to negate the need for manual con-
firmation on their proteomic data identification capabili-
ties. Clearly, repetition of scientific experiments using
different samples is a basic and vital scientific premise to
corroborate data, since the repeated identification of a
false positive is less likely as the number of repetitions
increases. Even though the massive amount of data
obtained from a single experiment already prohibits the
feasibility of manual data checking, we still found it nec-
essary to perform such checks, at least for mass spectrom-
etry based proteomics experiments where the goal of the
study is to identify a reference data set as a foundation for
future work, such as biomarker discovery.
Data congruence
Anderson et al. [23] investigated the congruence between
plasma proteins derived from four different sources. One
source was the literature, and the three others were exper-
imental, all MS-based and with immunoglobulin
removal, while the separation method was either at the
protein level using 2D-gel electrophoresis, at the peptide
level using 2D LC of trypsin-digested plasma, or a 'hybrid'
experiment with molecular mass fractionation followed
by 2D LC. A total of 1,175 proteins were identified from
the combined sources and of these, 980 occur in only 1
source. 195 proteins were found in at least 2 of the 4 data-
sets, 102 proteins were identified in only 2, and 47 pro-
teins were identified in 3 datasets. 46 proteins were found
in all 4 datasets, with only one protein having a single
transmembrane domain (inter-alpha-trypsin inhibitor
heavy chain H1), and one protein without a signal pep-
tide (hemoglobin beta chain). The authors state that the
absence of a transmembrane domain and the presence of
a signal peptide are characteristics of major plasma pro-
teins. Our set of 697 plasma proteins also identifies 45
proteins of the 46 found in those 4 sources (one entry is
an immunoglobulin). In 5 out of the 45 cases the primary
accession numbers chosen by Anderson and by us differ,
but the proteins identified were identical.
Additionally, Anderson et al. described 47 proteins that
were identified in 3 out of 4 sources, 1 of which was an
immunoglobulin, leaving 46 non-immunoglobulin pro-
teins. We identified 43 of those 46 proteins as well. The
three proteins we did not identify were 60-kDa heat shock
protein (we identified heat shock cognate 71 kDa protein
and heat shock 90 kDa protein 1, alpha, identified but
eliminated with validation), glutamate carboxypeptidase
II (84.3 kDa), and phosphoglycerate mutase 2 (28.6 kDa;
identified but eliminated with validation, however, we
identified phosphoglycerate mutase 1). Due to the tech-
nology applied it is reasonable to expect a certain degree
of variation in the protein profile identified between MS
runs. The molecular masses of the proteins are in the mid-
to higher mass category and so were likely not a major
deciding factor in determining why we did not identify
these proteins.
We did not extensively compare the 102 proteins that
Anderson reported to be identified in 2/4 sources because
we could not locate this list online. However, we were
able to identify some proteins from this category based on
visual inspection of the list published in Anderson et al.
Adiponectin, cathepsin D, selenoprotein P and squamous
cell carcinoma antigen 2 (Anderson reported the antigen
1 variant) are examples of proteins found to be in com-
mon between the two studies.
The types of keratins we identified represent what is com-
monly considered to be due to contamination. It is inter-
esting that the PPP high confidence set of 795 proteins
contains 24 (3.0%) 'keratin' entries. Our set of 697 pro-
teins contains 31 (4.4%) keratin entries. It appears as if
the keratin contamination problem is universal and is
rather equally represented across different research
groups. However, care should be taken not to categorize
all keratins as contaminants because certain keratins have
been identified as markers that define the degree of blad-
der squamous cell carcinoma differentiation [24]. Addi-
tionally, some keratins function as a diagnostic tool in
early stage [25] and higher stage bladder carcinoma [26].
For example, one of these marker keratins, cytokeratin
type 10 (keratin 10), is also part of our validated list of
697 proteins.
The number of 'Hypothetical proteins' is quite different
between datasets. The HUPO high confidence list (795
proteins) contains 172 hypothetical entries (22%), which
is far above our number of 30 hypothetical proteins
(4.3%). Anderson et al. [23] report only 3 hypothetical
proteins within their list of 195 confirmed proteins
(1.5%). It is worth noting that the HUPO list contains
immunoglobulin entries, whereas all of the Igs were
lumped into one accession because of high sequence sim-
ilarity (>95%) in the Anderson study. We have completely
removed immunoglobulins from our list of 697 high con-
fidence proteins for comparison purposes (see section
'Immunoglobulins' below).
Isoforms
Some investigators omit specific isoforms, thus simplify-
ing the picture by collapsing all protein isoforms into one
entry. Anderson et al. 2004 assigned all sequences that
shared a region larger than 15 amino acids and having
greater than 95% sequence identity to one single entry. By
doing this, it is likely that they have missed some splice
variants or specific protein isoforms. As reported in theBMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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results section, we subjected all of our protein sequences
to an 'All vs. All BLAST' search. After that, we verified all
proteins with 95% or greater sequence identity by visual
inspection to determine whether the identified peptides
matched the protein sequences they were assigned to, and
whether it was justified to maintain similar protein
sequences as separate entities rather than joining them
into one entry. Finally, we employed a peptide mapping
approach to identify any remaining redundancy in our
list, merging proteins together where appropriate and
assigning an annotation reflecting the accuracy of the
available information.
A database searching tool such as Mascot often retrieves a
specific isoform for a particular protein. However, upon
manual inspection, it is clear that many times the
sequenced peptide(s) do not specifically distinguish
between the different isoforms and thus reveal that the
isoform indicated by Mascot is not correct. In our dataset,
we claim identification of a specific protein isoform only
if there was at least one validated peptide identified that
specifically differentiated between the possible isoforms
for this particular protein. We believe that the extra step of
manually validating these isoforms is justified because
only an accurate and detailed plasma proteome can serve
as a reference for future biomarker discoveries and diag-
nostic applications.
Specific isoforms may not only be identified as having
specific tissue preferences but they may also be involved
in unique functions. The importance of specific isoforms
is exemplified by certain growth factors, such as TGF-beta
or enzymes such as superoxide dismutase (SOD). TGF-
beta1, -beta2, and -beta3 are isoforms that share high
sequence identity and play crucial and only partially over-
lapping roles in hematopoiesis [27], development, tumor
suppression, and wound healing [28]. SOD-1 is localized
in the cytosol, SOD-2 in mitochondria, and SOD-3 is
extracellular, and in addition to their unique subcellular
localization, all three isoforms have major and distinctive
responsibilities in the response process of vascular cells to
both acute and chronic oxidative stress [29]. While dis-
tinct subcellular localizations of specific isoforms are
quite often known, their specific functions remain to be
clarified in most cases. For example we identified the pro-
tein attractin, isoform 2 out of 5 possible isoforms. Iso-
form 1 is a type I membrane protein while 2–5 are
secreted proteins. Isoform 2 is the major isoform in
peripheral blood leukocytes, but nothing is reported
regarding the function(s) of this particular isoform. For
'heat shock cognate 71 kDa protein', the 7 unique pep-
tides that we identified can not distinguish between the
two splice isoforms 1 or 2. However, isoform 2 has a pro-
posed function as an endogenous inhibitory regulator of
HSC70, via competition with co-chaperones. Tropomy-
osin 1 alpha chain (TPM1) occurs in 5 isoforms of which
we identified isoform 2, 3, and 5. Isoform 1 is the skeletal
muscle variant, isoform 2 is the smooth muscle form, and
isoform 3 is the fibroblast form, while the primary locali-
zation for isoforms 4 or 5 has not been reported. Defects
in TPM1 are the cause of familial hypertrophic cardiomy-
opathy 3 (CMH3) with a high risk of cardiac failure and
sudden cardiac death. At any rate, the overall homology
between isoforms quite often exceeds 95% and blindly
combining sequences with high similarity defeats the
detailed identification of isoforms and splice variants,
which may be necessary in order to distinguish between a
healthy versus a diseased state.
Immunoglobulins
As stated previously, we have chosen to remove the immu-
noglobulins (144) from our analysis to facilitate compar-
ison of our data with other studies. However, we feel that
analysis of the immunoglobulins is important for some of
the same reasons that we provide in the "Isoforms" sec-
tion above. We therefore provide a supplement to this
work which is available on line [see Additional file 1]. The
supplement contains a list of the immunoglobulins that
we identified in this study although we have not analysed
this list extensively for redundancy or to confirm that the
peptides isolated completely map to their assigned pro-
tein sequences.
Cellular component
With regard to the categorization of the plasma proteins
into their cellular components according to the gene
ontology consortium (GoMiner, http://www.geneontol
ogy.org), Anderson et al. showed that their set of 1,175
distinct proteins consisted of 27% extracellular proteins,
while the other 73% were cellular proteins (membrane,
nuclear, cytoplasmic etc.). The 195 proteins that were
identified by at least two sources, and which Anderson
called the "confirmed set of plasma proteins", showed a
different distribution. In this case, 50% of the proteins
were classified as 'extracellular'. Of the 46 proteins that
were identified by 4/4 sources and confirmed in the
present study as well, 68% were classified as 'extracellular'.
The clear increase in the proportion of 'extracellular' pro-
teins seems to come in parallel with the increased confi-
dence of an identified plasma protein set. Chan et al. [21]
subjected their 1444 proteins to a gene ontology classifi-
cation as well, finding a distribution of 40.3% intracellu-
lar, 32.65% membrane, and 6.9% cell fraction; this was
summarized by an approximately 80% cellular fraction
versus  a 15–20% extracellular fraction. Pieper et al. [2]
classified 47.5% of their 325 distinct proteins as extracel-
lular (38.8% as classical plasma proteins, 8.9% other
extracellular fluids). The rest were classified as vesicular
proteins (incl. ER, Golgi etc.), cell membrane, and intrac-
ellular proteins.BMC Medical Genomics 2008, 1:41 http://www.biomedcentral.com/1755-8794/1/41
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As we mentioned previously (see Results), 77% of our 697
proteins were recognized as part of the GoMiner cellular
component category. Of these, 35% were classified as
'extracellular' and 65% as cellular. It is possible that the
proportion of extracellular proteins would change if our
entire set of identified proteins could have been classified.
If the accuracy of our list can be gauged based on the pro-
portion of extracellular proteins it contains, then the rela-
tively high proportion of extracellular proteins in our list
seems to reinforce the confidence of our identified plasma
protein set.
Interestingly, if we perform a GoMiner analysis on the 242
proteins common to both our and the HUPO datasets,
227/242 (86%) of the protein IPI numbers are recognized
with 208 being classified as "cellular component" by the
program. As with the analysis of the BPPD dataset, some
proteins appear in more than one category. GoMiner clas-
sified 98 (40%; normalized as in Results) proteins as cel-
lular and as expected, a high percentage of proteins were
classified as extracellular (146 proteins or 60%; normal-
ized as in Results) (Figure 10, panel A). 18 of the extracel-
lular proteins were classified as extracellular matrix
proteins, leaving 128 "true" plasma proteins. It is more
probable that independent investigators will co-identify
classical plasma proteins rather than cellular proteins that
might be found in plasma only as a consequence of tissue
remodeling or cell death. These cellular proteins are likely
to be found in the plasma only at certain points in time,
so it is less plausible that independent groups will co-
identify the same cellular proteins, given the disparate
nature of their samples.
Comparison of the molecular weights of the 242 overlap-
ping proteins between ours and the HUPO data sets
shows a rather well-balanced distribution (Figure 10,
panel B). Most proteins identified in our high confidence
set of 697 proteins are clearly found in the 15–45 kDa
range (see Figure 3). However, while the 242 overlapping
proteins are also mainly from the range 15–45 kDa, they
are very closely followed in proportion by the other MW
groups with a MW ≥ 45 and up to 100 kDa. The common
group of 242 proteins thus represents a cross section of
plasma proteins that spans most of the possible MW
range. The overlapping protein MW profile (Figure 10,
panel B) does not resemble a MW profile as seen for a typ-
ical plasma analysis (Figure 3), or for the overlapping pro-
teins identified within this study between the FT and
Orbitrap mass spectrometers (Figure 9, panel A).
Conclusion
The effort of the PPP by HUPO to standardize plasma/
serum handling techniques and data analysis was a big
step in the right direction. With this work we hope to con-
tribute to this effort and to the urgent task of identifying
the true nature of the human blood plasma proteome,
which holds the potential for more comprehensive diag-
nostics and crucial biomarker discoveries. Even though
the mass spectrometric methodologies and technologies
currently employed are not yet able to cover the 9–12 log
plasma protein concentration range, mass spectrometry-
based proteomics is the 'discovery tool' of choice.
Researchers are investigating alternative strategies that
could help to reduce the complexity of plasma, and mass
spectrometry manufacturers are continuously striving to
improve the instrumentation. The latest hybrid mass spec-
trometer, the LTQ-Orbitrap, has been put through the
acid test [30,31] and is proving itself as a very effective,
high sensitivity mass spectrometer, requiring less mainte-
nance and being less expensive than the LTQ-FTICR.
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